CHO V08
Alternative Names: CHO-V08; Glyconjugate Klebsiella pneumoniae bivalent vaccine - CHO pharma; V-08Latest Information Update: 11 Jul 2025
At a glance
- Originator CHO Pharma
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Klebsiella infections
Most Recent Events
- 26 Jun 2025 Phase-I clinical trials in Klebsiella infections (Prevention) in Taiwan (Parenteral) (NCT07016152)
- 11 Jun 2025 CHO Pharma plans a phase I trial for Klebsiella infections (Prevention) (In volunteers) in Taiwan (Parenteral) in June 2025 (NCT07016152)
- 11 Jun 2025 Preclinical trials in Klebsiella infections (Prevention) in Taiwan (Parenteral)